Therapeutic Reprogramming, Hybrid Stem Cells and Maturation

• US 20090263357A1
• Filed: 01/11/2008
• Published: 10/22/2009
• Est. Priority Date: 01/16/2002
• Status: Abandoned Application

• Current Assignee: PrimeGen Biotech LLC
• Original Assignee: PrimeGen Biotech LLC
• Inventors: Silva, Francisco J., Sayre, Chauncey B.
• Application Number:
  US12/013,282
• Publication Number:
  US 20090263357A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2517/04 Cells produced using nuclear transfer
• CPC Class Codes: C12N 5/0611 Primordial germ cells, e.g. embryonic germ cells [EG]

Abstract

Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent either a more differentiated state or a less differentiated state after contact with stimulatory factors. The therapeutically reprogrammed cells are suitable for cellular regenerative therapy and have the potential to differentiate into more committed cell lineages. Additionally, hybrid stem cells suitable for therapeutic reprogramming and cellular regenerative therapy are provided.

Claims

1. A therapeutic reprogramming method comprising:

isolating a stem cell;

contacting said stem cell with a medium comprising stimulatory factors which induce development of said stem cell into a therapeutically reprogrammed cell;

recovering said therapeutically reprogrammed cell from said medium; and

implanting said therapeutically reprogrammed cell, or a cell matured therefrom, into a host in need of a therapeutically reprogrammed cell.

2. The therapeutic reprogramming method of claim 1 wherein said stem cell is selected from the group consisting of embryonic stem cells, fetal stem cells, somatic stem cells, multipotent adult progenitor cells, modified germ cells, adipose-derived stem cells and primordial sex cells.

3. The therapeutic reprogramming method of claim 2 wherein said stem cell is an embryonic stem cell.

4. The therapeutic reprogramming method of claim 2 wherein said stem cell is a fetal stem cell.

5. The therapeutic reprogramming method of claim 2 wherein said stem cell is a somatic stem cell.

6. The therapeutic reprogramming method of claim 2 wherein said stem cell is a multipotent adult progenitor cell.

7. The therapeutic reprogramming method of claim 2 wherein said stem cell is a modified germ cell.

8. The therapeutic reprogramming method of claim 2 wherein said stem cell is an adipose-derived stem cell.

9. The therapeutic reprogramming method of claim 2 wherein said stem cell is a primordial sex cell.

10. The therapeutic reprogramming method of claim 9 wherein said primordial sex cell is a spermatogonial stem cell.

11. The therapeutic reprogramming method of claim 1 wherein said stimulatory factor is selected from the group consisting of chemicals, biochemicals, and cellular extracts.

12. The therapeutic reprogramming method of claim 11 wherein said stimulatory factor is a chemical selected from the group consisting of 5-aza-2′

-deoxycytidine, histone deacetylase inhibitor, n-butyric acid and trichostatin A.

13. The therapeutic reprogramming method of claim 12 wherein said chemical is 5-aza-2′

-deoxycytidine.

14. The therapeutic reprogramming method of claim 11 wherein said stimulatory factor is a cellular extract selected from the group consisting of whole cell extracts, cytoplast extracts and karyoplast extracts.

15. The therapeutic reprogramming method of claim 14 wherein said stimulatory factor is a karyoplast extract.

16. The therapeutic reprogramming method of claim 14 wherein said cellular extract is isolated from a stem cell.

17. The therapeutic reprogramming method of claim 16 wherein said stem cell is selected from the group consisting of embryonic stem cells, fetal neural stem cells, multipotent adult progenitor cells, and primordial sex cells.

18. The therapeutic reprogramming method of claim 1 wherein said host is a mammal.

19. The therapeutic reprogramming method of claim 18 wherein said mammal is a human.

20. The therapeutic reprogramming method of claim 1 wherein said stem cell is isolated from said host.

21. The therapeutic reprogramming method of claim 1 further comprising the step of maturing said therapeutically reprogrammed cell to become committed to a tissue-specific lineage.

22. A therapeutically reprogrammed cell comprising:

an SSC which has been exposed to stimulatory factors which have caused said SSC to mature or differentiate into a totipotent or a pluripotent cell.

23. A therapeutically reprogrammed cell comprising:

a pluripotent stem cell which has been exposed to stimulatory factors which have caused said pluripotent stem cell to mature or differentiate into a more committed cell lineage.